Gelonghui April 25 | Buchang Pharmaceutical (603858.SH) released its 2023 annual report. During the reporting period, the company\’s operating income was 13.245 billion yuan, a year-on-year decrease of 11.41%; the net profit attributable to shareholders of the listed company was 319 million yuan, a year-on-year loss. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 292 million yuan, turning a loss into a profit; the basic earnings per share was 0.2884 yuan per share. It is planned to distribute a cash dividend of 1.26 yuan (tax included) to all shareholders for every 10 shares.
Gelonghui April 25 | Buchang Pharmaceutical (603858.SH) released its 2023 annual report. During the reporting period, the company\’s operating income was 13.245 billion yuan, a year-on-year decrease of 11.41%; the net profit attributable to shareholders of the listed company was 319 million yuan, a year-on-year loss. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 292 million yuan, turning a loss into a profit; the basic earnings per share was 0.2884 yuan per share.
It is planned to distribute a cash dividend of 1.26 yuan (tax included) to all shareholders for every 10 shares.
